Details of the Drug

General Information of Drug (ID: DM5PU6O)

Drug Name

Oxcarbazepine

Synonyms

Epilexter; Epliga; Oxacarbazepine; Oxcarbamazepine; Oxcarbazepime; Oxcarbazepina; Oxcarbazepinum; Timox; Trileptal; Desitin brand of oxcarbazepine; Novartis brand of oxcarbazepine; Oxcarbazepine [INN]; GP 47680; O0363; GP-47680; KIN-493; Oxaleptal (TN); Oxcarbazepina [INN-Spanish]; Oxcarbazepinum [INN-Latin]; SPN-804; Trileptal (TN); Oxcarbazepine (USAN/INN); 10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Epilepsy	8A60-8A68	Approved	[1]
Focal epilepsy	N.A.	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Anticonvulsants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

252.27

Logarithm of the Partition Coefficient (xlogp)

1.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 34 micromol/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 4.5 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: 95% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The clearance of drug is 84.9 L/h [6]
Elimination: Following oral administration, more than 95% of the administered dose of oxcarbazepine is found in the urine [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 hours [3]
Metabolism: The drug is metabolized via reduction by several members of the aldo-keto reductase family of cytosolic liver enzymes [7]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 135.9034 micromolar/kg/day [8]
Vd: The volume of distribution (Vd) of drug is 49 L [6]
Water Solubility: The ability of drug to dissolve in water is measured as 0.085 mg/mL [4]

Chemical Identifiers

Formula: C15H12N2O2
IUPAC Name: 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
Canonical SMILES: C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N
InChI: InChI=1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)
InChIKey: CTRLABGOLIVAIY-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 34312
ChEBI ID: CHEBI:7824
CAS Number: 28721-07-5
DrugBank ID: DB00776
TTD ID: D0QL3P
VARIDT ID: DR00453
INTEDE ID: DR1744
ACDINA ID: D00500

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.9 (SCN11A)	TTN9VTF	SCNBA_HUMAN	Blocker	[9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Biotransformations	[11]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Biotransformations	[11]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Biotransformations	[11]
Aldo-keto reductase family 1 member C4 (AKR1C4)	OTW2MMOF	AK1C4_HUMAN	Biotransformations	[11]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Gene/Protein Processing	[12]
Carbonyl reductase 1 (CBR1)	OTQ3A541	CBR1_HUMAN	Biotransformations	[11]
Carbonyl reductase 3 (CBR3)	OT9G6SF0	CBR3_HUMAN	Biotransformations	[11]
Dehydrogenase/reductase SDR family member 7 (DHRS7)	OTV729DT	DHRS7_HUMAN	Biotransformations	[13]
HLA class I histocompatibility antigen, B alpha chain (HLA-B)	OTNXFWY2	HLAB_HUMAN	Drug Response	[14]
Sex hormone-binding globulin (SHBG)	OTPWU5IW	SHBG_HUMAN	Gene/Protein Processing	[15]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Oxcarbazepine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Zonisamide	DM0DTF7	Moderate	Increased metabolism of Oxcarbazepine caused by Zonisamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Primidone	DM0WX6I	Moderate	Increased metabolism of Oxcarbazepine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Tiagabine	DMKSQG0	Moderate	Increased metabolism of Oxcarbazepine caused by Tiagabine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Stiripentol	DMMSDOY	Moderate	Increased metabolism of Oxcarbazepine caused by Stiripentol mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Oxcarbazepine caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Clonazepam	DMTO13J	Moderate	Increased metabolism of Oxcarbazepine caused by Clonazepam mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Oxcarbazepine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
-----------


⏷ Show the Full List of 7 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Oxcarbazepine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Oxcarbazepine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[19]
Repaglinide	DM5SXUV	Moderate	Increased metabolism of Oxcarbazepine caused by Repaglinide mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[20]
Pioglitazone	DMKJ485	Moderate	Increased metabolism of Oxcarbazepine caused by Pioglitazone mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[17]
Midostaurin	DMI6E0R	Moderate	Increased metabolism of Oxcarbazepine caused by Midostaurin mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[21]
Gilteritinib	DMTI0ZO	Moderate	Increased metabolism of Oxcarbazepine caused by Gilteritinib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[22]
Oliceridine	DM6MDCF	Major	Increased metabolism of Oxcarbazepine caused by Oliceridine mediated induction of CYP450 enzyme.	Acute pain [MG31]	[23]
Donepezil	DMIYG7Z	Moderate	Increased metabolism of Oxcarbazepine caused by Donepezil mediated induction of CYP450 enzyme.	Alzheimer disease [8A20]	[17]
Ivabradine	DM0L594	Moderate	Increased metabolism of Oxcarbazepine caused by Ivabradine mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[18]
Bepridil	DM0RKS4	Moderate	Increased metabolism of Oxcarbazepine caused by Bepridil mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[17]
Dronedarone	DMA8FS5	Moderate	Increased metabolism of Oxcarbazepine caused by Dronedarone mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[24]
Nifedipine	DMSVOZT	Moderate	Increased metabolism of Oxcarbazepine caused by Nifedipine mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[17]
Bedaquiline	DM3906J	Moderate	Increased metabolism of Oxcarbazepine caused by Bedaquiline mediated induction of CYP450 enzyme.	Antimicrobial drug resistance [MG50-MG52]	[25]
Cilostazol	DMZMSCT	Moderate	Decreased metabolism of Oxcarbazepine caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[26]
Clarithromycin	DM4M1SG	Moderate	Increased metabolism of Oxcarbazepine caused by Clarithromycin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[17]
Telithromycin	DMZ4P3A	Moderate	Increased metabolism of Oxcarbazepine caused by Telithromycin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[27]
Cariprazine	DMJYDVK	Moderate	Increased metabolism of Oxcarbazepine caused by Cariprazine mediated induction of CYP450 enzyme.	Bipolar disorder [6A60]	[18]
Ixabepilone	DM2OZ3G	Moderate	Increased metabolism of Oxcarbazepine caused by Ixabepilone mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Lapatinib	DM3BH1Y	Moderate	Increased metabolism of Oxcarbazepine caused by Lapatinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[23]
Exemestane	DM9HPW3	Moderate	Increased metabolism of Oxcarbazepine caused by Exemestane mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[29]
Esterified estrogens	DM9KZDO	Moderate	Increased metabolism of Oxcarbazepine caused by Esterified estrogens mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[30]
Tucatinib	DMBESUA	Moderate	Increased metabolism of Oxcarbazepine caused by Tucatinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[31]
Palbociclib	DMD7L94	Moderate	Increased metabolism of Oxcarbazepine caused by Palbociclib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[23]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Oxcarbazepine caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[32]
Letrozole	DMH07Y3	Moderate	Increased metabolism of Oxcarbazepine caused by Letrozole mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[17]
Quinestrol	DMJ6H1Z	Moderate	Increased metabolism of Oxcarbazepine caused by Quinestrol mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[30]
Cabazitaxel	DMPAZHC	Moderate	Increased metabolism of Oxcarbazepine caused by Cabazitaxel mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[33]
Bosutinib	DMTI8YE	Moderate	Increased metabolism of Oxcarbazepine caused by Bosutinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[34]
Estradiol	DMUNTE3	Moderate	Increased metabolism of Oxcarbazepine caused by Estradiol mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[30]
Atorvastatin	DMF28YC	Moderate	Increased metabolism of Oxcarbazepine caused by Atorvastatin mediated induction of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[35]
Macitentan	DMP79A1	Moderate	Increased metabolism of Oxcarbazepine caused by Macitentan mediated induction of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[36]
Doxercalciferol	DM6FG1P	Moderate	Increased metabolism of Oxcarbazepine caused by Doxercalciferol mediated induction of CYP450 enzyme.	Chronic kidney disease [GB61]	[37]
PF-04449913	DMSB068	Moderate	Increased metabolism of Oxcarbazepine caused by PF-04449913 mediated induction of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[38]
Dihydrocodeine	DMB0FWL	Moderate	Increased metabolism of Oxcarbazepine caused by Dihydrocodeine mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[17]
Levomilnacipran	DMV26S8	Moderate	Antagonize the effect of Oxcarbazepine when combined with Levomilnacipran.	Chronic pain [MG30]	[39]
Drospirenone	DM1A9W3	Major	Increased metabolism of Oxcarbazepine caused by Drospirenone mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[30]
Levonorgestrel	DM1DP7T	Major	Increased metabolism of Oxcarbazepine caused by Levonorgestrel mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[30]
Ulipristal	DMBNI20	Moderate	Increased metabolism of Oxcarbazepine caused by Ulipristal mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[18]
Norgestimate	DMYP4XC	Major	Increased metabolism of Oxcarbazepine caused by Norgestimate mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[40]
Levobupivacaine	DM783CH	Minor	Increased metabolism of Oxcarbazepine caused by Levobupivacaine mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[41]
Halothane	DM80OZ5	Moderate	Increased metabolism of Oxcarbazepine caused by Halothane mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[17]
Cocaine	DMSOX7I	Moderate	Increased metabolism of Oxcarbazepine caused by Cocaine mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[17]
Alfentanil	DMVO0UB	Moderate	Increased metabolism of Oxcarbazepine caused by Alfentanil mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[42]
Mifepristone	DMGZQEF	Moderate	Increased metabolism of Oxcarbazepine caused by Mifepristone mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[43]
Osilodrostat	DMIJC9X	Moderate	Increased metabolism of Oxcarbazepine caused by Osilodrostat mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[44]
Ivacaftor	DMZC1HS	Moderate	Increased metabolism of Oxcarbazepine caused by Ivacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[45]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Oxcarbazepine and Ethanol.	Cystitis [GC00]	[46]
Rivaroxaban	DMQMBZ1	Moderate	Increased metabolism of Oxcarbazepine caused by Rivaroxaban mediated induction of CYP450 enzyme.	Deep vein thrombosis [BD71]	[47]
Sertraline	DM0FB1J	Moderate	Antagonize the effect of Oxcarbazepine when combined with Sertraline.	Depression [6A70-6A7Z]	[39]
Vilazodone	DM4LECQ	Moderate	Antagonize the effect of Oxcarbazepine when combined with Vilazodone.	Depression [6A70-6A7Z]	[39]
Nefazodone	DM4ZS8M	Moderate	Increased metabolism of Oxcarbazepine caused by Nefazodone mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[17]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Oxcarbazepine and Selegiline.	Depression [6A70-6A7Z]	[19]
Vortioxetine	DM6F1PU	Moderate	Antagonize the effect of Oxcarbazepine when combined with Vortioxetine.	Depression [6A70-6A7Z]	[39]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Oxcarbazepine and Isocarboxazid.	Depression [6A70-6A7Z]	[19]
Milnacipran	DMBFE74	Moderate	Antagonize the effect of Oxcarbazepine when combined with Milnacipran.	Depression [6A70-6A7Z]	[39]
Escitalopram	DMFK9HG	Moderate	Decreased metabolism of Oxcarbazepine caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[48]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of hyponatremia by the combination of Oxcarbazepine and Desvenlafaxine.	Depression [6A70-6A7Z]	[39]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of Oxcarbazepine and Phenelzine.	Depression [6A70-6A7Z]	[19]
Clomipramine	DMINRKW	Moderate	Decreased metabolism of Oxcarbazepine caused by Clomipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[23]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Oxcarbazepine and Esketamine.	Depression [6A70-6A7Z]	[23]
[3H]estrone-3-sulphate	DMGPF0N	Moderate	Increased metabolism of Oxcarbazepine caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme.	Discovery agent [N.A.]	[49]
Oxybutynine	DMJPBAX	Moderate	Increased metabolism of Oxcarbazepine caused by Oxybutynine mediated induction of CYP450 enzyme.	Discovery agent [N.A.]	[17]
Oestradiol valerate and dienogest	DMZK0FQ	Major	Increased metabolism of Oxcarbazepine caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme.	Endometriosis [GA10]	[40]
Praziquantel	DMOU1PK	Moderate	Increased metabolism of Oxcarbazepine caused by Praziquantel mediated induction of CYP450 enzyme.	Flatworm infection [1F70-1F86]	[50]
Bay 80-6946	DMLOS5R	Moderate	Accelerated clearance of Oxcarbazepine due to the transporter induction by Bay 80-6946.	Follicular lymphoma [2A80]	[51]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Oxcarbazepine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[52]
Solifenacin	DMG592Q	Moderate	Increased metabolism of Oxcarbazepine caused by Solifenacin mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[53]
Mirabegron	DMS1GYT	Minor	Increased metabolism of Oxcarbazepine caused by Mirabegron mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[54]
Tolterodine	DMSHPW8	Moderate	Increased metabolism of Oxcarbazepine caused by Tolterodine mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[17]
Itraconazole	DMCR1MV	Moderate	Increased metabolism of Oxcarbazepine caused by Itraconazole mediated induction of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[17]
Ketoconazole	DMPZI3Q	Moderate	Increased metabolism of Oxcarbazepine caused by Ketoconazole mediated induction of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[17]
Dexlansoprazole	DM1DBV5	Moderate	Decreased metabolism of Oxcarbazepine caused by Dexlansoprazole mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[23]
Sunitinib	DMCBJSR	Moderate	Increased metabolism of Oxcarbazepine caused by Sunitinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[23]
Avapritinib	DMK2GZX	Moderate	Increased metabolism of Oxcarbazepine caused by Avapritinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[18]
Boceprevir	DMBSHMF	Moderate	Increased metabolism of Oxcarbazepine caused by Boceprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[55]
PSI-7977	DMLSUWZ	Major	Accelerated clearance of Oxcarbazepine due to the transporter induction by PSI-7977.	Hepatitis virus infection [1E50-1E51]	[23]
Simeprevir	DMLUA9D	Major	Increased metabolism of Oxcarbazepine caused by Simeprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[56]
Telaprevir	DMMRV29	Moderate	Increased metabolism of Oxcarbazepine caused by Telaprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[55]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Oxcarbazepine caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[57]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Oxcarbazepine and Procarbazine.	Hodgkin lymphoma [2B30]	[19]
MK-1439	DM215WE	Major	Increased metabolism of Oxcarbazepine caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Fostemsavir	DM50ILT	Minor	Increased metabolism of Oxcarbazepine caused by Fostemsavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[59]
Cobicistat	DM6L4H2	Moderate	Increased metabolism of Oxcarbazepine caused by Cobicistat mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[48]
Tipranavir	DM8HJX6	Moderate	Increased metabolism of Oxcarbazepine caused by Tipranavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Dolutegravir	DMCZGRE	Major	Increased metabolism of Oxcarbazepine caused by Dolutegravir mediated induction of UGT.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Saquinavir	DMG814N	Moderate	Increased metabolism of Oxcarbazepine caused by Saquinavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Elvitegravir	DMG9B1U	Moderate	Increased metabolism of Oxcarbazepine caused by Elvitegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Oxcarbazepine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Rilpivirine	DMJ0QOW	Major	Increased metabolism of Oxcarbazepine caused by Rilpivirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Darunavir	DMN3GCH	Moderate	Increased metabolism of Oxcarbazepine caused by Darunavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Atazanavir	DMSYRBX	Moderate	Increased metabolism of Oxcarbazepine caused by Atazanavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
GSK1265744	DMT8J0I	Major	Increased metabolism of Oxcarbazepine caused by GSK1265744 mediated induction of UGT.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Maraviroc	DMTL94F	Moderate	Accelerated clearance of Oxcarbazepine due to the transporter induction by Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Paricalcitol	DMYBV3G	Moderate	Increased metabolism of Oxcarbazepine caused by Paricalcitol mediated induction of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[37]
Levamlodipine	DM92S6N	Moderate	Increased metabolism of Oxcarbazepine caused by Levamlodipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[17]
Felodipine	DMOSW35	Moderate	Increased metabolism of Oxcarbazepine caused by Felodipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[17]
Tolvaptan	DMIWFRL	Moderate	Increased metabolism of Oxcarbazepine caused by Tolvaptan mediated induction of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[18]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Oxcarbazepine caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[18]
Suvorexant	DM0E6S3	Moderate	Increased metabolism of Oxcarbazepine caused by Suvorexant mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[64]
Triazolam	DMETYK5	Moderate	Increased metabolism of Oxcarbazepine caused by Triazolam mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[17]
Tasimelteon	DMLOQ1V	Moderate	Increased metabolism of Oxcarbazepine caused by Tasimelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[65]
ITI-007	DMUQ1DO	Major	Increased metabolism of Oxcarbazepine caused by ITI-007 mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[66]
Quazepam	DMY4D87	Moderate	Decreased metabolism of Oxcarbazepine caused by Quazepam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[23]
Estazolam	DMZGXUM	Moderate	Increased metabolism of Oxcarbazepine caused by Estazolam mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[17]
Naloxegol	DML0B41	Moderate	Increased metabolism of Oxcarbazepine caused by Naloxegol mediated induction of CYP450 enzyme.	Large intestine motility disorder [DB32]	[67]
Pemigatinib	DM819JF	Moderate	Increased metabolism of Oxcarbazepine caused by Pemigatinib mediated induction of CYP450 enzyme.	Liver cancer [2C12]	[18]
Crizotinib	DM4F29C	Moderate	Increased metabolism of Oxcarbazepine caused by Crizotinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[63]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Oxcarbazepine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[23]
Ceritinib	DMB920Z	Moderate	Increased metabolism of Oxcarbazepine caused by Ceritinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[68]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Oxcarbazepine caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[69]
Capmatinib	DMYCXKL	Moderate	Increased metabolism of Oxcarbazepine caused by Capmatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[70]
Artemether	DM48QOT	Moderate	Increased metabolism of Oxcarbazepine caused by Artemether mediated induction of CYP450 enzyme.	Malaria [1F40-1F45]	[23]
Hydroxychloroquine	DMSIVND	Moderate	Antagonize the effect of Oxcarbazepine when combined with Hydroxychloroquine.	Malaria [1F40-1F45]	[23]
Idelalisib	DM602WT	Moderate	Increased metabolism of Oxcarbazepine caused by Idelalisib mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[71]
GDC-0199	DMH0QKA	Moderate	Increased metabolism of Oxcarbazepine caused by GDC-0199 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[72]
IPI-145	DMWA24P	Moderate	Increased metabolism of Oxcarbazepine caused by IPI-145 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[73]
Acalabrutinib	DM7GCVW	Moderate	Increased metabolism of Oxcarbazepine caused by Acalabrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[74]
Ibrutinib	DMHZCPO	Moderate	Increased metabolism of Oxcarbazepine caused by Ibrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[75]
Ponatinib	DMYGJQO	Moderate	Increased metabolism of Oxcarbazepine caused by Ponatinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[23]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Oxcarbazepine caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[76]
Selumetinib	DMC7W6R	Moderate	Increased metabolism of Oxcarbazepine caused by Selumetinib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[77]
Ethinyl estradiol	DMODJ40	Major	Increased metabolism of Oxcarbazepine caused by Ethinyl estradiol mediated induction of CYP450 enzyme.	Menopausal disorder [GA30]	[40]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Oxcarbazepine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[78]
Ubrogepant	DM749I3	Moderate	Increased metabolism of Oxcarbazepine caused by Ubrogepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[79]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Oxcarbazepine and Lasmiditan.	Migraine [8A80]	[80]
Dihydrotachysterol	DMFB97P	Moderate	Increased metabolism of Oxcarbazepine caused by Dihydrotachysterol mediated induction of CYP450 enzyme.	Mineral deficiency [5B5K]	[37]
Panobinostat	DM58WKG	Moderate	Increased metabolism of Oxcarbazepine caused by Panobinostat mediated induction of CYP450 enzyme.	Multiple myeloma [2A83]	[81]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Oxcarbazepine and Thalidomide.	Multiple myeloma [2A83]	[82]
Nilotinib	DM7HXWT	Moderate	Increased metabolism of Oxcarbazepine caused by Nilotinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[83]
Ruxolitinib	DM7Q98D	Moderate	Increased metabolism of Oxcarbazepine caused by Ruxolitinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[84]
Dasatinib	DMJV2EK	Moderate	Increased metabolism of Oxcarbazepine caused by Dasatinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[23]
Busulfan	DMXYJ9C	Moderate	Increased metabolism of Oxcarbazepine caused by Busulfan mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[17]
Rolapitant	DM8XP26	Moderate	Increased metabolism of Oxcarbazepine caused by Rolapitant mediated induction of CYP450 enzyme.	Nausea/vomiting [MD90]	[85]
Ondansetron	DMOTQ1I	Moderate	Increased metabolism of Oxcarbazepine caused by Ondansetron mediated induction of CYP450 enzyme.	Nausea/vomiting [MD90]	[17]
E-2007	DMJDYNQ	Moderate	Increased metabolism of Oxcarbazepine caused by E-2007 mediated induction of CYP450 enzyme.	Neuropathy [8C0Z]	[18]
Entrectinib	DMMPTLH	Moderate	Increased metabolism of Oxcarbazepine caused by Entrectinib mediated induction of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[86]
Sibutramine	DMFJTDI	Moderate	Increased metabolism of Oxcarbazepine caused by Sibutramine mediated induction of CYP450 enzyme.	Obesity [5B80-5B81]	[17]
Levomethadyl Acetate	DM06HG5	Major	Increased metabolism of Oxcarbazepine caused by Levomethadyl Acetate mediated induction of CYP450 enzyme.	Opioid use disorder [6C43]	[57]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Oxcarbazepine caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[23]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Oxcarbazepine and Buprenorphine.	Pain [MG30-MG3Z]	[87]
Hydrocodone	DMQ2JO5	Major	Increased metabolism of Oxcarbazepine caused by Hydrocodone mediated induction of CYP450 enzyme.	Pain [MG30-MG3Z]	[23]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Oxcarbazepine and Rasagiline.	Parkinsonism [8A00]	[19]
Pimavanserin	DMR7IVC	Moderate	Increased metabolism of Oxcarbazepine caused by Pimavanserin mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[88]
Bromocriptine	DMVE3TK	Moderate	Increased metabolism of Oxcarbazepine caused by Bromocriptine mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[17]
Macimorelin	DMQYJIR	Moderate	Increased metabolism of Oxcarbazepine caused by Macimorelin mediated induction of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[89]
Lefamulin	DME6G97	Moderate	Increased metabolism of Oxcarbazepine caused by Lefamulin mediated induction of CYP450 enzyme.	Pneumonia [CA40]	[90]
Ergonovine	DM0VEC1	Moderate	Increased metabolism of Oxcarbazepine caused by Ergonovine mediated induction of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[23]
Lonafarnib	DMGM2Z6	Moderate	Increased metabolism of Oxcarbazepine caused by Lonafarnib mediated induction of CYP450 enzyme.	Premature ageing appearance [LD2B]	[91]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Oxcarbazepine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[92]
Darolutamide	DMV7YFT	Moderate	Increased metabolism of Oxcarbazepine caused by Darolutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[93]
Silodosin	DMJSBT6	Moderate	Accelerated clearance of Oxcarbazepine due to the transporter induction by Silodosin.	Prostate hyperplasia [GA90]	[23]
Apremilast	DMTWS9E	Moderate	Increased metabolism of Oxcarbazepine caused by Apremilast mediated induction of CYP450 enzyme.	Psoriasis [EA90]	[94]
Riociguat	DMXBLMP	Moderate	Increased metabolism of Oxcarbazepine caused by Riociguat mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[95]
Everolimus	DM8X2EH	Moderate	Accelerated clearance of Oxcarbazepine due to the transporter induction by Everolimus.	Renal cell carcinoma [2C90]	[23]
Axitinib	DMGVH6N	Moderate	Increased metabolism of Oxcarbazepine caused by Axitinib mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[96]
Temsirolimus	DMS104F	Moderate	Increased metabolism of Oxcarbazepine caused by Temsirolimus mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[23]
Tofacitinib	DMBS370	Moderate	Increased metabolism of Oxcarbazepine caused by Tofacitinib mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[23]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Oxcarbazepine caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[17]
Quetiapine	DM1N62C	Moderate	Increased metabolism of Oxcarbazepine caused by Quetiapine mediated induction of CYP450 enzyme.	Schizophrenia [6A20]	[23]
Aripiprazole	DM3NUMH	Moderate	Increased metabolism of Oxcarbazepine caused by Aripiprazole mediated induction of CYP450 enzyme.	Schizophrenia [6A20]	[97]
Fentanyl	DM8WAHT	Major	Increased metabolism of Oxcarbazepine caused by Fentanyl mediated induction of CYP450 enzyme.	Sensation disturbance [MB40]	[23]
Avanafil	DM75CXN	Moderate	Increased metabolism of Oxcarbazepine caused by Avanafil mediated induction of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[98]
Tadalafil	DMJZHT1	Moderate	Increased metabolism of Oxcarbazepine caused by Tadalafil mediated induction of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[18]
LDE225	DMM9F25	Moderate	Increased metabolism of Oxcarbazepine caused by LDE225 mediated induction of CYP450 enzyme.	Skin cancer [2C30-2C37]	[99]
Larotrectinib	DM26CQR	Moderate	Increased metabolism of Oxcarbazepine caused by Larotrectinib mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[23]
Methylprednisolone	DM4BDON	Moderate	Increased metabolism of Oxcarbazepine caused by Methylprednisolone mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[17]
Ifosfamide	DMCT3I8	Moderate	Increased metabolism of Oxcarbazepine caused by Ifosfamide mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[17]
Docetaxel	DMDI269	Moderate	Increased metabolism of Oxcarbazepine caused by Docetaxel mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[100]
Trabectedin	DMG3Y89	Moderate	Increased metabolism of Oxcarbazepine caused by Trabectedin mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Armodafinil	DMGB035	Moderate	Increased metabolism of Oxcarbazepine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[101]
LEE011	DMMX75K	Moderate	Increased metabolism of Oxcarbazepine caused by LEE011 mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[23]
Prednisolone	DMQ8FR2	Moderate	Increased metabolism of Oxcarbazepine caused by Prednisolone mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[17]
Taxol	DMUOT9V	Moderate	Increased metabolism of Oxcarbazepine caused by Taxol mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[102]
Doxorubicin	DMVP5YE	Moderate	Increased metabolism of Oxcarbazepine caused by Doxorubicin mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Fostamatinib	DM6AUHV	Moderate	Increased metabolism of Oxcarbazepine caused by Fostamatinib mediated induction of CYP450 enzyme.	Thrombocytopenia [3B64]	[103]
Apixaban	DM89JLN	Moderate	Increased metabolism of Oxcarbazepine caused by Apixaban mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[104]
Cabozantinib	DMIYDT4	Moderate	Increased metabolism of Oxcarbazepine caused by Cabozantinib mediated induction of CYP450 enzyme.	Thyroid cancer [2D10]	[105]
Sirolimus	DMGW1ID	Moderate	Increased metabolism of Oxcarbazepine caused by Sirolimus mediated induction of CYP450 enzyme.	Transplant rejection [NE84]	[23]
Saxagliptin	DMGXENV	Moderate	Increased metabolism of Oxcarbazepine caused by Saxagliptin mediated induction of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[106]
Linagliptin	DMWFJTR	Moderate	Accelerated clearance of Oxcarbazepine due to the transporter induction by Linagliptin.	Type 2 diabetes mellitus [5A11]	[107]
Elagolix	DMB2C0E	Moderate	Accelerated clearance of Oxcarbazepine due to the transporter induction by Elagolix.	Uterine fibroid [2E86]	[108]
Betrixaban	DM2C4RF	Moderate	Accelerated clearance of Oxcarbazepine due to the transporter induction by Betrixaban.	Venous thromboembolism [BD72]	[109]
Amiodarone	DMUTEX3	Moderate	Increased metabolism of Oxcarbazepine caused by Amiodarone mediated induction of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[17]
-----------


⏷ Show the Full List of 182 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Meglumine	E00181	8567	Buffering agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 2000	E00649	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Oxcarbazepine 300 mg tablet	300 mg	24 HR Extended Release Oral Tablet	Oral
Oxcarbazepine 150 mg tablet	150 mg	24 HR Extended Release Oral Tablet	Oral
Oxcarbazepine 600 mg tablet	600 mg	24 HR Extended Release Oral Tablet	Oral
Oxcarbazepine 150 mg tablet	150 mg	Oral Tablet	Oral
Oxcarbazepine 300 mg tablet	300 mg	Oral Tablet	Oral
Oxcarbazepine 600 mg tablet	600 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7254).
2	Oxcarbazepine FDA Label
3	DailyMed Label: TRILEPTAL (oxcarbazepine) film-coated tablets or suspension, for oral use
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Antunes NJ, van Dijkman SC, Lanchote VL, Wichert-Ana L, Coelho EB, Alexandre Junior V, Takayanagui OM, Tozatto E, van Hasselt JGC, Della Pasqua O: Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. Eur J Pharm Sci. 2017 Nov 15;109S:S116-S123. doi: 10.1016/j.ejps.2017.05.034. Epub 2017 May 17.
7	Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T: Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5.
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
10	The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
11	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
12	Inhibition of human aromatase complex (CYP19) by antiepileptic drugs. Toxicol In Vitro. 2008 Feb;22(1):146-53.
13	Biochemical properties of human dehydrogenase/reductase (SDR family) member 7. Chem Biol Interact. 2014 Jan 25;207:52-7. doi: 10.1016/j.cbi.2013.11.003. Epub 2013 Nov 16.
14	Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010 Mar;11(3):349-56. doi: 10.2217/pgs.09.162.
15	Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology. 2001 Jan 9;56(1):31-6. doi: 10.1212/wnl.56.1.31.
16	Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
17	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
18	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
20	Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
21	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
22	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
23	Cerner Multum, Inc. "Australian Product Information.".
24	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
25	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
26	Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
27	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
28	Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
29	Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
30	Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
31	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
32	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
33	Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
34	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
35	Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
36	Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
37	Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
38	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39	Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
40	Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
41	Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
42	Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
43	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
44	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
45	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
46	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
47	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
48	Canadian Pharmacists Association.
49	Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
50	Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
51	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
52	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
53	Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
54	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
55	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
56	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
57	Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
58	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
59	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
60	Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
61	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
62	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
63	Cerner Multum, Inc. "Canadian Product Information.".
64	Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
65	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
66	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
67	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
68	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
69	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
70	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
71	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
72	Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
73	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
74	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
75	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
76	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
77	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
78	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
79	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
80	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
81	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
82	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
83	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
84	Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
85	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
86	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
87	Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
88	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
89	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
90	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
91	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
92	Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
93	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
94	Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
95	Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
96	Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
97	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
98	Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
99	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
100	Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
101	Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
102	Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
103	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
104	Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
105	Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
106	Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
107	Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
108	Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
109	Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]